Last updated: February 14, 2026
What Is the Development Status of Linifanib?
Linifanib (ABT-700) is an investigational tyrosine kinase inhibitor primarily targeting vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptors. Its development has focused on oncology, specifically in treating solid tumors such as non-small cell lung cancer (NSCLC), hepatocellular carcinoma, and thyroid cancers.
Development milestones include:
- Early Clinical Trials: Phase 1 trials confirmed the drug's safety profile, involving dose-escalation studies in advanced solid tumor patients.
- Phase 2 Trials: Focused on efficacy in specific cancers, including NSCLC, alongside biomarker analyses to identify responsive subpopulations.
- Latest Status: As of 2022, the candidate’s development has been discontinued or paused by multiple companies due to limited efficacy signals, development prioritization shifts, and strategic considerations (source: ClinicalTrials.gov; company press releases).
No ongoing Phase 3 trials or regulatory filings appear in the public domain presently. The development pipeline for linifanib is largely inactive in major markets.
What Are the Key Data Points on Linifanib’s Clinical Performance?
Efficacy:
- In Phase 2 NSCLC trials, objective response rates hovered around 4-8%, with median progression-free survival ranging from 2.3 to 3.2 months. These outcomes fell short of market competitors like bevacizumab or ramucirumab, which demonstrated higher response rates.
Safety/Tolerability:
- Dose-limiting toxicities included hypertension, fatigue, diarrhea, and elevated liver enzymes.
- Adverse events were typically manageable, with discontinuations due to adverse effects occurring in fewer than 10% of patients.
Regulatory Status:
- No approval by FDA or EMA.
- Development discontinuation communicated by partners before reaching regulatory submission stages.
Intellectual Property:
- Patent protection for linifanib peaked around 2020, with most key patents expiring by 2030. These patents covered composition and specific uses in oncology.
How Does Linifanib Compare with Competitors?
| Drug |
Targeted Pathway |
Approval Status |
Indications |
Response Rate / PFS |
| Linifanib |
VEGF, PDGF |
Discontinued |
None |
4–8% response / 2–3 months PFS |
| Bevacizumab |
VEGF |
Approved |
NSCLC, colorectal, other cancers |
Up to 15–20% response / 4–7 months PFS |
| Ramucirumab |
VEGFR2 |
Approved |
NSCLC, gastric cancer, others |
Response rates 8–12% / Up to 5 months PFS |
| Sorafenib |
Multi-kinase, including VEGFR |
Approved |
Hepatocellular carcinoma, kidney cancer |
Response 2–3%, PFS ~2–3 months |
Linifanib’s efficacy metrics are inferior to many approved VEGF pathway inhibitors, impacting its commercial viability.
What Is the Market Outlook for Linifanib?
The current landscape for angiogenesis inhibitors in oncology is dominated by a handful of established agents with proven survival benefits. The failure to demonstrate superior efficacy or safety improvements diminishes the likelihood of regulatory approval or commercial success for linifanib.
Market size estimates:
- The global oncology drug market was valued at approximately $160 billion in 2022.
- VEGF inhibitors represented a significant share, with revenues exceeding $20 billion annually.
- The segment for first-line treatments in NSCLC is competitive, with drugs like pembrolizumab and chemotherapy combinations outperforming VEGF inhibitors in survival metrics.
Projected penetration:
- Given the clinical data and competitive landscape, linifanib’s potential market share is negligible without compelling efficacy or safety advantages.
- A shift toward immunotherapy and targeted agents with proven survival benefits makes entry prospects for new VEGF inhibitors minimal.
Regulatory and strategic considerations:
- Without new clinical data or favorable biomarker studies, regulatory agencies are unlikely to approve linifanib.
- Companies may consider licensing or divestment strategies for existing assets, but ongoing development is unlikely unless new positive data emerge.
What Are the Implications for Investment and R&D?
Investors should consider:
- The limited clinical and commercial prospects of linifanib in its current form.
- The strategic shift in oncology toward immunotherapies and targeted agents with survival benefits.
- The potential for repurposing in non-oncology indications, though no such studies are publicly announced.
Companies focusing on VEGF pathway inhibitors are reallocating R&D toward combination therapies and immuno-oncology, further diminishing linifanib's market potential.
Key Takeaways
- Linifanib has completed early-phase clinical trials with limited efficacy signals.
- Development has largely been halted, with no current plans for regulatory submission.
- Competitive pressures and clinical performance diminish prospects for market entry.
- The anti-angiogenesis market favors established therapies with survival benefits.
- Future viability depends on positive clinical data, which currently does not exist.
FAQs
Q1: Has linifanib received FDA approval?
A1: No, it has not reached regulatory approval stages.
Q2: Are there ongoing clinical trials for linifanib?
A2: As of 2022, no publicly registered trials are ongoing.
Q3: Could linifanib find a role outside oncology?
A3: Currently, there are no indications of alternative development pathways.
Q4: How does linifanib’s efficacy compare to approved VEGF inhibitors?
A4: It demonstrates lower response rates and shorter progression-free survival times.
Q5: What is the main reason for the halt in linifanib development?
A5: Insufficient efficacy data and stiff competition from established therapies.
Citations:
[1] ClinicalTrials.gov entries for linifanib.
[2] Company press releases, 2022.
[3] Market research reports on oncology drug markets.
